GlassScriptPhysician profile
Sara R Cunningham
NPI 1447278007
$3,724.74
in general payments reported to CMS, 2019-2025
49 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $986 · 2022: $271 · 2023: $615 · 2024: $1,033 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448 · Education: $19.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.94 |
| Education | $19.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $628.90 | 2021-2025 | Airsupra, Fasenra, Farxiga |
| Lilly USA, LLC | $393.92 | 2021-2024 | Mounjaro, Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.65 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Abbvie INC. | $316.37 | 2023-2025 | |
| Novo Nordisk INC | $275.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $189.17 | 2023-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $161.17 | 2023-2025 | |
| Amgen INC. | $111.64 | 2024-2025 | Enbrel, Otezla, Evenity |
| Glaxosmithkline, LLC. | $101.28 | 2021-2025 | Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $99.60 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.86 | 2025 | Caplyta |
| Harmony Biosciences LLC | $65.78 | 2023-2024 | Wakix |
| Mylan Specialty L.P. | $61.11 | 2021-2024 | Yupelri |
| Gilead Sciences, INC. | $50.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $49.41 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.